Study of AMV564 in Subjects With Advanced Solid Tumors

Key Inclusion Criteria: * 18 years of age or older * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 * Histologically or cytologically documented, incurable or metastatic solid tumor that is advanced (non-resectable) or recurrent and progressing since the last anti-tumor therapy and for which no recognized standard therapy exists * Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or per other criteria best suited for the specific tumor type being evaluated * Willing to complete all scheduled visits and assessments at the institution administering therapy Key Exclusion Criteria: * Treatment with any local or systemic antineoplastic therapy (including chemotherapy, hormonal therapy, or radiation) within 3 weeks prior to first dose of AMV564 * Major trauma or major surgery within 4 weeks prior to first dose of AMV564 * Prior treatment with chimeric antigen receptor (CAR) T-cell therapy or T-cell engager therapy * Chronic use of corticosteroids in excess of 10 mg daily of prednisone or equivalent within 4 weeks prior to first dose of AMV564 * Adverse events from prior anti-cancer therapy that have not resolved to Grade ≤ 1 except for alopecia * Known, central nervous system (CNS) disease involvement, or prior history of National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Grade ≥ 3 drug-related CNS toxicity